Company profile: Theratechnologies
1.1 - Company Overview
Company description
- Provider of biopharmaceutical therapies, including Trogarzo for HIV in individuals with limited treatment options due to resistance, intolerance, or safety considerations; EGRIFTA SV (tesamorelin) to reduce excess abdominal fat in HIV patients with lipodystrophy; and Long Acting Peptides and the SORT1+ oncology platform. Pipeline includes tesamorelin for NASH, F8 bioequivalent formulation, and a multi-dose pen injector in development.
Products and services
- EGRIFTA SV: A formulation-optimized tesamorelin reducing excess abdominal fat in HIV-infected patients with lipodystrophy, engineered to deliver therapeutic abdominal adipose reduction per its defined formulation characteristics
- Trogarzo: An antiretroviral-class medication that treats HIV in individuals with limited options due to resistance, intolerance, or safety considerations, built to address refractory or contraindicated therapeutic scenarios
- SORT1+ Technology: A biomarker-targeted proprietary oncology platform that develops therapies targeting sortilin-positive cancers, architected to advance therapeutic programs explicitly focused on malignancies expressing sortilin
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Theratechnologies
Biocrates
HQ: Austria
Website
- Description: Provider of metabolomics platforms for biomarker discovery and validation in complex diseases. Offers the MxP Quant 500 XL kit for profiling >1,000 compounds, WebIDQ software, MetaboINDICATOR, and data interpretation and statistical analysis services, alongside automated sample preparation integrated with mass-spectrometric methods.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biocrates company profile →
Corline Biomedical
HQ: Sweden
Website
- Description: Provider of heparin-based solutions to improve kidney transplantation, cell therapies and regenerative medicine. Offers Renaparin to enhance kidney transplant outcomes and Cytoparin for cell therapies and treatment of type 1 diabetes, using proprietary heparin technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Corline Biomedical company profile →
PhaseBio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical drug development targeting cardiovascular, endocrine, and metabolic disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full PhaseBio company profile →
Artara Therapeutics
HQ: United States
Website
- Description: Provider of investigational cell and intravenous therapies, including TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations based on immunopotentiator OK-432, and IV Choline Chloride to address choline deficiency in patients on parenteral nutrition, aiming to be the first FDA-approved IV choline formulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Artara Therapeutics company profile →
Captozyme
HQ: United States
Website
- Description: Provider of therapeutic enzyme-based biotechnology products for health and wellness, dedicated to helping people better manage diets and overall health. Developing Nephure, a product that enables people to enjoy foods they love without adding oxalate to their bodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Captozyme company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Theratechnologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Theratechnologies
2.2 - Growth funds investing in similar companies to Theratechnologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Theratechnologies
4.2 - Public trading comparable groups for Theratechnologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →